← ANALYST RATINGS · TIPRANKS
Rezolute (RZLT): analyst forecast and price target
Analyst consensus
Strong Buy8 Buy0 Hold0 Sell
Ratings of 8 analysts in the last 3 months12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $10.00, the highest $15.00, the lowest $6.00. The average is +179.3% from the last price of $3.58.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Jason McCarthy★★★★★★★★★★#12398 · hits 30% · avg −13.6% | Maxim Group | $14.00 | Buy | +291.1% | Reiterated | 15.10.26on TipRanks Oct 16 11:25 | −8.1%next day −7.1% | ↗ |
| Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% | H.C. Wainwright | $10.00 | Buy | +179.3% | Reiterated | 15.10.26on TipRanks 07:14 | −8.1%next day −7.1% | ↗ |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $5.00 → $4.50−10.0% | Hold | +25.7% | Reiterated | 15.10.26on TipRanks Oct 14 21:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $5.00 → $4.50−10.0% | Hold | +25.7% | Reiterated | 15.10.26on TipRanks Oct 14 21:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.50 | Hold | +25.7% | Upgrade | 15.10.26on TipRanks Oct 14 21:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $5.00 → $4.50−10.0% | Hold | +25.7% | Reiterated | 15.10.26on TipRanks Oct 14 21:05 | — | |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $6.00 | Buy | +67.6% | Reiterated | 14.10.26on TipRanks Oct 15 06:10 | −7.2%next day −8.1% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.50 → $5.00+11.1% | Hold | +39.7% | Reiterated | 11.10.26on TipRanks 02:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.50 → $5.00+11.1% | Hold | +39.7% | Reiterated | 11.10.26on TipRanks 02:05 | — | |
| Daniel Brims★★★★★★★★★★#12312 · hits 19% · avg −36.9% | Lake Street | $9.00 → $12.00+33.3% | Buy | +235.2% | Reiterated | 06.10.26on TipRanks 08:50 | −0.8%next day +1.6% · 5 days +6.9% | ↗ |
| Jason Butler★★★★★★★★★★#412 · hits 51% · avg +18.3% | Citizens JMP | $11.00 → $15.00+36.4% | Buy | +319.0% | Reiterated | 06.10.26on TipRanks 05:50 | −0.8%next day +1.6% · 5 days +6.9% | ↗ |
| Pete Stavropoulos★★★★★★★★★★#2065 · hits 45% · avg +16.4% | Cantor Fitzgerald | — | Buy | — | Upgrade | 05.10.26on TipRanks 17:05 | −0.8%next day +1.6% · 5 days +6.9% | ↗ |
| Yun Zhong★★★★★★★★★★#12228 · hits 38% · avg −9.6% | Wedbush | $6.00 | Buy | +67.6% | Reiterated | 05.10.26on TipRanks 11:15 | +7.3%next day −0.8% · 5 days +12.0% | ↗ |
| Albert Lowe★★★★★★★★★★#3118 · hits 41% · avg +8.2% | Craig-Hallum | $4.00 → $7.00+75.0% | Buy | +95.5% | Upgrade | 29.09.26on TipRanks 07:15 | −2.0%next day +1.4% · 5 days +3.7% | ↗ |
| Debjit Chattopadhyay★★★★★★★★★★#506 · hits 48% · avg +17.0% | Guggenheim | $6.00 → $11.00+83.3% | Buy | +207.3% | Assigned | 15.06.26on TipRanks 06:45 | +6.5%next day +6.1% · 5 days +15.5% | ↗ |
| Catherine Novack★★★★★★★★★★#905 · hits 41% · avg +25.1% | JonesTrading | $6.00 | Buy | +67.6% | Reiterated | 02.06.26on TipRanks Jun 25 09:25 | +10.7%next day +15.2% · 5 days +0.5% | ↗ |
| Maury Raycroft★★★★★★★★★★#1326 · hits 44% · avg +12.0% | Jefferies | $15.00 → $20.00+33.3% | Buy | +458.7% | Reiterated | 08.12.25on TipRanks Dec 5 16:20 | −2.1%next day −3.1% · 5 days −83.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Rezolute
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $8.00 at a price of $4.14 (+93.2%); now: $10.00 at $3.58 (+179.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 12 | 12 | 6 | 4 | 9 |
| Buy | 0 | 4 | 5 | 6 | 3 | 6 |
| Hold | 2 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q1 2027, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.18 (from $-0.23 to $-0.14). Last quarter: $-0.20.
Best top-analyst consensus in the sector · Healthcare
About Rezolute
- CEO: Nevan Charles Elam
- Employees: 58
- 275 Shoreline Drive, Redwood City, CA, 94065, US
- www.rezolutebio.com
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Data from the stock’s TipRanks forecast page, read 2 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗